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930Type II endoleak is an enigmatic and unpredictable
marker of worse outcome after endovascular
aneurysm repair
Enrico Cieri, MD, PhD,a Paola De Rango, MD, PhD,a Giacomo Isernia, MD,a Gioele Simonte, MD,a
Andrea Ciucci, MD,a Gianbattista Parlani, MD,a Fabio Verzini, MD, PhD, FEBVS,a and
Piergiorgio Cao, MD, FRCS,b Perugia and Rome, Italy
Background: This study analyzed predictors and the long-term consequence of type II endoleak in a large series of elective
endovascular abdominal aneurysm repairs (EVARs).
Methods: Baseline characteristics and operative and follow-up data of consecutive patients undergoing EVAR were
prospectively collected. Patients who developed type II endoleak according to computed tomography angiography and
those without type II endoleak were compared for baseline characteristics, mortality, reintervention, conversion, and
aneurysm growth after repair.
Results: In 1997-2011, 1412 consecutive patients (91.4% males; mean age, 72.9 years) underwent elective EVAR and
were subsequently followed up for a median of 45 months (interquartile range, 21-79 months). Type II endoleak
developed in 218. Adjusted analysis failed to identify signiﬁcant independent predictors for type II endoleak with the
exception of age (odds ratio, 1.03; 95% conﬁdence interval, 1.01-1.05; P[ .003) and intraluminal thrombus (odds ratio,
0.69; 95% conﬁdence interval, 0.53-0.92; P [ .010). Type II endoleak rates were comparable regardless of the device
model. Late aneurysm-related survival was comparable (98.4% vs 99.5% at 60 months; P [ .73) in patients with and
without type II endoleak. However, at 60 months after EVAR, rates of aneurysm sac growth >5 mm (35.3% vs 3.3%; P <
.0001) were higher in patients with type II endoleak. Cox regression identiﬁed type II endoleak as an independent
predictor of aneurysm growth along with age and cardiac disease. The presence of type II endoleak led to reinterventions
in 40% of patients and conversion to open surgery in 8%. However, assessment of these patients after reintervention
showed similar 60-month freedom rates of persisting type II endoleak (present in more than two after computed
tomography angiography scan studies) among those with and without reinterventions (49.8% vs 45.6%; P [ .639).
Aneurysm growth >5 mm persisted with comparable rates in type II endoleak patients after reintervention and in those
who remained untreated (42.9% vs 57.4% at 60 months; P [ .117).
Conclusions: Reintervention for type II endoleak was common in our practice, yet such intervention did not reliably
prevent the continued expansion of the abdominal aortic aneurysm. Our data indicate type II endoleak appears to be
a marker of EVAR failure that is difﬁcult to predict and treat effectively. (J Vasc Surg 2014;59:930-7.)The clinical relevance and natural history of type II
endoleaks, the most common category of endoleaks
recorded after an endovascular abdominal aneurysm repair
(EVAR), remain largely unsettled. Currently, there is no
evidence to support a single optimal threshold for interven-
tion or the best treatment strategy in patients with isolated
type II endoleak.1 The long-term success for treating type
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(AAA) growth after secondary interventions for type II
endoleak. However, data are limited on whether type II
endoleaks are predictable, preventable, and treatable, and
consistent debate remains.2-4
The objective of this study was to analyze promoting
factors, associated outcomes, and effect of reintervention
in type II endoleak in EVAR patients.METHODS
The study analyzed consecutive patients who under-
went elective EVAR for infrarenal AAAs between April
1997 and December 2011 and were entered in a prospec-
tive database. Collected data included preoperative demo-
graphics, comorbidities, morphology, intraoperative
details, and follow-up information. Patients treated with
fenestrated stent grafts or treated emergently for AAA
rupture were excluded.
EVAR was performed by a dedicated team, with the
patient under general or local anesthesia. Different device
models were used depending on the aortoiliac morphology,
stent graft availability, and operator preferences. Devices
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and currently in use.5
After EVAR, patients were scheduled for serial follow-
up imaging with duplex ultrasound and computed tomog-
raphy angiography (CTA) scan at 1 month, 6 months, and
yearly thereafter. Postoperative surveillance was performed
using multiphasic CTA with 3-mm cuts, including imaging
before the administration of contrast material, after the
intravenous administration of contrast material in the arte-
rial phase (arterial phase), and in postcontrast delayed
phase (venous phase). The TeraRecon Aquarius dedicated
digital workstation (Terarecon, Foster City, Calif) was used
for CTA scan imaging analysis and three-dimensional
reconstructions.
Preoperative and postoperative CTA scans were
compared, and aneurysm sac diameter and endoleak was
recorded. Maximum aneurysm diameter was determined
by the shortest diagonal of the cross-sectional CTA image
perpendicular to the centerline of ﬂow on CTA reconstruc-
tions. Diameter changes >5 mm between two studies after
CTA were considered signiﬁcant for sac growth based on
the Standardized Reporting Practices in Vascular Surgery.6
Type II endoleak was deﬁned as blood ﬂow outside the
stent graft but within the aneurysm sac caused by retro-
grade reﬁlling from aortic side branches as assessed on
imaging.6 Diagnosis of type II endoleak was made using
contrast imaging with delayed-enhancement phase. Duplex
ultrasound ﬁndings were always retested with a contrast-
enhanced CTA scan or angiography before treatment
(conservative, strict surveillance, embolization) was
planned. Arterial and delayed-phase imaging was used in
the post-EVAR CTA protocol for type II endoleak detec-
tion. Reintervention for type II endoleak was performed
at the discretion of the attending surgeon, but treatment
was applied when AAAs showed a persisting type II endo-
leak (present in two or more post-EVAR CTA scans) asso-
ciated with diameter growth >5 mm after EVAR.
Type of treatment was individualized to aneurysm
anatomy and endoleak source. Lumbar endoleaks were
generally accessed through retrograde cannulation of ilio-
lumbar arteries from hypogastric arteries, followed by
spirals and coils embolization.7 Direct sac puncture with
a spinal needle using CTA guidance and coil embolization
was an alternative treatment performed less frequently.
Type II inferior mesenteric artery (IMA) endoleaks
were commonly embolized by retrograde access to the
IMA through the arc of Riolan or the marginal artery after
the middle colic artery was accessed through the superior
mesenteric artery.3,8
Primary outcome measures were mortality and
freedom from aneurysm growth. Secondary outcome
measures included aneurysm-related mortality, endoleak
persistence, and the rate of reintervention and conversion
to open surgery.
Statistical analysis. Patients were separately analyzed
according to the presence or absence of type II endoleak.
Patients with type II endoleak were further categorized
according to treatment applied, and those receiving ornot receiving reintervention after EVAR were compared
for long-term outcomes.
Categoric factors are summarized using frequencies
and percentages, and continuous measures are reported
using means and standard deviations or the median and
interquartile range (IQR), when appropriate. Comparisons
between groups were analyzed for signiﬁcance using c2
tests, analysis of variance, t-test, or the Fisher exact test,
when appropriate.
The independent associations with type II endoleak
and aneurysm growth were tested with Cox regression
analyses. The most reported and clinically relevant
morphology and patient-related predictors of aneurysm
growth and endoleak in literature were introduced into
the Cox model. Backward stepwise selection was used to
exclude confounders and select signiﬁcant predictors
retained in the ﬁnal model. Results are expressed as odds
ratios (ORs) and correspondent 95% conﬁdence intervals
(CIs). To estimate survival, aneurysm-related survival rates
of reintervention, conversion, and aneurysm growth,
Kaplan-Meier analysis with log-rank test to determine
signiﬁcance of comparison was used. Signiﬁcance was
assumed at P < .05. Analyses were performed using SPSS
20.0 software (IBM Corp, Armonk, NY).
RESULTS
During the study period, 1412 (91.4%males; mean age,
72.9 years) consecutive elective EVARs were performed
with different device models. At a median follow-up of
45 months (IQR, 21-79 months), 218 type II endoleaks
were recorded. Baseline characteristics of patients with and
without type II endoleak are reported in Table I.
Predictors of type II endoleak. Type II endoleak
rates were comparable regardless of the type of device,
but there was a tendency for lower rates with the most
recent generation devices (Table II). Cox regression anal-
ysis adjusted for covariates (age, sex, diabetes, smoking,
hypertension, hyperlipidemia, coronary disease, chronic
obstructive pulmonary disease, peripheral artery disease,
AAA diameter, use of anticoagulants, intraluminal
thrombus) identiﬁed old age (continuous variable) as
a positive predictor of type II endoleak (OR, 1.03; 95% CI,
1.01-1.05; P ¼ .003). The presence of intraluminal aortic
thrombus was the only indicator of decreased type II
endoleak occurrence (OR, 0.69; 95% CI, 0.53-0.92;
P ¼ .010).
Survival and aneurysm-related survival. All-cause
survival was higher in patients who developed type II endo-
leak: 88.4% vs 79.7% at 36 months and 76.1% vs 67% at
60 months in patients with and without type II endoleak,
respectively (P ¼ .01).
Aneurysm-related survival was indeed comparable:
rates were 100% vs 99.5% at 36 months and 98.4% vs
99.5% at 60 months for patients with and without type II
endoleak, respectively (P ¼ .730).
Overall, 17 aneurysm ruptures occurred over a media-
n of 55 months (IQR, 42-75 months) after EVAR and
due to development of type I (n ¼ 5), II (n ¼ 4), and
Table I. Baseline characteristics and demographics of
patients with and without type II endoleak
Variablea
Type II
endoleak
(n ¼ 218)
No type II
endoleak
(n ¼ 1194) P
Age, years 73.7 6 6.9 72.8 6 7.8 .106
Males 194 (89.0) 1096 (91.8) .113
Hypertension 171 (78.4) 913 (76.5) .295
CAD 102 (46.8) 555 (46.5) .496
Hyperlipidemia 69 (31.7) 428 (35.8) .132
PAD 21 (9.6) 162 (13.6) .066
Diabetes 28 (12.8) 147 (12.3) .45
COPD 101 (46.3) 595 (49.8) .190
Chronic renal failure 28 (12.8) 173 (14.5) .301
Smoking 113 (51.8) 704 (59.0) .03
Cerebrovascular disease 25 (11.5) 168 (14.1) .179
Anticoagulants 19 (8.7) 82 (6.9) .201
Antiplatelet 118 (54.1) 594 (49.7) .132
Aneurysm diameter, mm 53 (49-58) 53 (50-59) .256
Neck length, mm 25 (20-30) 23 (18-30) .072
Neck diameter, mm 23 (21-24) 23 (22-25) .155
Neck thrombusb 5 (2.3) 83 (7.0) .004
Aortic thrombusc 101 (46.3) 594 (49.7) .196
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary
disease; IQR, interquartile range; PAD, peripheral artery disease.
aContinuous data are shown as the mean 6 standard deviation or median
(IQR) and categoric data are shown as number (%).
bA continuous parietal layer of thrombus at least three-fourths the
circumference in one section.
cSevere if >50% of the circumference.
Table II. Type II endoleak distribution by device
models
Device No.
Type II endoleak
(n ¼ 218),
No type II endoleak
(n ¼ 1194),
PNo. (%) No. (%)
Zenitha 610 95 (43.6) 515 (43.1) .480
Excluderb 233 38 (17.4) 195 (16.3) .376
Endurantc 73 4 (1.8) 69 (5.8) .007
Talentc 167 21 (9.6) 147 (12.2) .164
AneuRxc 235 39 (17.9) 196 (16.4) .326
Anacondad 53 11 (5.0) 42 (3.5) .182
Fortrone 35 10 (4.6) 25 (2.1) .033
Others 6
New devices 882 129 (59.2) 753 (63.1) .155
aCook Medical, Bloomington, Ind.
bW. L. Gore & Associates, Flagstaff, Ariz.
cMedtronic, Santa Rosa, Calif.
dTerumo Vascutek, Inchinnan Renfrewshire, Scotland, UK.
eJohnson & Johnson-Cordis Corporation, Bridgewater, NJ.
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(n ¼ 2), or iliac aneurysm rupture. The four ruptures in the
patients with type II endoleak occurred at 42, 43, 55, and
74 months after EVAR. In one patient, rupture occurred
1 year after unsuccessful IMA embolization and in another,
type I endoleak was also recorded at the time of rupture.
Aneurysm growth at follow-up. Rates of freedom
from aneurysm growth are shown in Fig 1. There was
a signiﬁcant higher proportion of growth >5 mm in thegroup of aneurysms with type II endoleak than in those
without: 15.5% vs 1.9% at 36 months and 35.3% vs 3.3% at
60 months (P < .0001).
Cox regression analysis (adjusting for age, coronary
disease, diabetes, smoking, hypertension, chronic renal
failure, peripheral artery disease, type II endoleak, hyperlip-
idemia, AAA diameter, on anticoagulant) conﬁrmed
a strong independent association between type II endoleak
and the likelihood of aneurysm growth after EVAR (OR,
4.93; 95% CI, 3.62-6.72; P < .0001). Less relevant inde-
pendent association with aneurysm growth was also shown
for old age (OR, 1.03; 95% CI, 1.01-1.06; P ¼ .006) and
history of coronary disease (OR, 1.49; 95% CI, 1.09-2.03;
P ¼ .012).
Reintervention during follow-up. During follow-up,
52 patients with type II endoleak associated with aneurysm
growth underwent reinterventions, and in 15, more than
one reintervention was undertaken. Details of reinterven-
tions are reported in Tables III and IV.
Reintervention rates were more common in patients
with type II endoleak compared with the others. Freedom
from reintervention rates were 79.0% vs 97.5% at 36months
and 60.2% vs 94.9% at 60 months for patients with and
without type II endoleak, respectively (P < .0001; Fig 2).
A total of 31 late conversions to open surgery were per-
formed, 21 of which were in the type II endoleak group. In
11 patients with type II endoleak, a previous reintervention
had already been performed with unsuccessful outcome
before conversion: 1 IMA embolization, 4 lumbar emboli-
zations, and 6 additional extension cuffs. Conversion rates
were signiﬁcantly higher in patients who displayed type II
endoleak: freedom rates were 97% vs 99.3% at 36 months
and 92.2% vs 98.9% at 60 months for patients with and
without type II endoleak (P < .0001).
Twenty-two aneurysms with type II endoleak of the 52
that received reintervention continued to enlarge. Aneu-
rysm growth rates after reintervention were comparable
between patients with type II endoleak treated with reinter-
vention and those without treatment: 28.6% vs 39.5% at
36 months, 42.9% vs 57.4% at 60 months (P¼ .117; Fig 3).
Kaplan-Meier estimates of freedom from type II endo-
leak persistence after reintervention also showed propor-
tions comparable to those of patients with type II
endoleak without reintervention: 65.7% vs 64% at
36 months and 49.8% vs 45.6% at 60 months in patients
with type II endoleak receiving reintervention and those
left untreated, respectively (P ¼ .639). The evolution of
type II endoleak is summarized in Fig 4.
DISCUSSION
Despite the high prevalence (10% to 30% in most
series) and the increasing number of studies investigating
the nature and evolution, type II endoleaks remain obscure
events that can be assumed as generic markers of negative
prognosis after EVAR.3,9-12 Precise characterization of type
II endoleaks as “benign” or “threatening” events is unreli-
able, because it is likely that multiple adverse factors, with
different clinical relevance, are all similarly labeled as
Fig 1. Freedom from aneurysm growth >5 mm in patients with and without type II endoleak according to Kaplan-
Meier analysis. Curves are displayed up to a value of a standard error of <10%.
Table III. Reintervention for type II endoleak treatment
(35 patients undergoing single reintervention)
Type of reintervention
Patients (n ¼ 35),
No. (%)
IMA embolization 10 (29)
Lumbar embolization 7 (20)
Aneurysm sac embolization 1 (3)
CT-guided sac embolization 7 (20)
Hypogastric
Embolization þ iliac cuff 8 (23)
Surgical ligature 1 (3)
IMA laparoscopic clipping 1 (3)
CT, Computed tomography; IMA, inferior mesenteric artery.
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aortic sac is their more immediate manifestation. However,
given the large variability, any unique characterization of
type II endoleak allows for fallacious optimal treatment.
The multiple implications of the commonly labeled type
II endoleak are also shown by variability in reporting in
published studies: “early,” “delayed,” “persisting,” “spon-
taneously disappearing,” “pressurized,” but also “intermit-
tent” or “recurrent” type II endoleak have been identiﬁed,
without clear indication because the variable behavior is
indeed related to missing information.13This study failed to show relevant modiﬁable predictors
of type II endoleak. The only independent variables
selected with Cox analysis were advanced age and intralu-
minal thrombus. A number of other studies also suggested
aortic thrombus load and patency of aortic branches as the
most common important anatomic predictors of type II
endoleaks.12,14-16 However, even if these suggested predic-
tors could be identiﬁed, there is little chance to adjust their
effect on risk: these are all nonmodiﬁable factors that do
not allow effective strategies to preclude or effectively
reverse type II endoleaks, which therefore appear to be
unpreventable occurrences. Studies also showed that
preventive coil/embolization of patent aortic branches
before EVAR may be of little beneﬁt on the occurrence
of type II endoleak and aneurysm shrinkage.16 Further-
more, the categorization of aortic thrombus lacks standard-
ization, whereas the exact number of patent aortic branches
is not always recognized in routine preoperative CTA
imaging.
Even if potential causes of type II endoleak are treated,
there is little evidence that treatment is effective. In this
series, 35.3% of patients with type II endoleak had
a >5 mm growing sac at 60 months. Of these, only
a minority was successfully treated, because 22 of 52
continued to grow after reintervention. Furthermore, almost
half of the treated type II endoleaks persisted after treat-
ment. The quite high number of late conversion to open
Table IV. Reinterventions for type II endoleak treatment (15 patients undergoing more than one reintervention)
Patient First reintervention Secondary reintervention Tertiary reintervention
1 Lumbar embolization IMA embolization
2 Lumbar embolization IMA embolization Hypogastric embolization þ iliac cuff
3 Hypogastric embolization þ iliac cuff CT-guided embolization .
4 CT-guided embolization IMA embolization .
5 IMA embolization Sac embolization .
6 Angiography (embolization attempt) Surgical sac suture around stent graft .
7 Angiography (embolization attempt) CT-guided embolization .
8 Angiography (embolization attempt) CT-guided embolization .
9 Angiography (embolization attempt) CT-guided embolization .
10 Angiography (embolization attempt) CT-guided embolization .
11 Angiography (embolization attempt) Hypogastric embolization þ iliac cuff .
12 Angiography (embolization attempt) Hypogastric embolization þ iliac cuff .
13 Angiography (embolization attempt) Transcaval embolization .
14 Angiography (embolization attempt) Transcaval embolization Hypogastric embolization þ iliac cuff
15 Angiography (embolization attempt) Lumbar embolization .
CT, Computed tomography; IMA, inferior mesenteric artery.
Fig 2. Freedom from reintervention in patients with and without type II endoleak according to Kaplan-Meier analysis.
Curves are displayed up to a value of a standard error of <10%.
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higher risk of unfavorable outcome exposure in type II
endoleak aneurysms (5-year conversion rate of 2% in those
without type II endoleak). Therefore, only a few patients
with type II endoleak would beneﬁt from treatment.
Other experienced centers reported similar unsuccess-
ful treatment outcome for type II endoleak. Aziz et al2analyzed results at 23 months after type II endoleak embo-
lization and found no differences in the rates of aneurysm
growth before and after type II endoleak treatment.
Follow-up imaging of recurrent or persisting endoleak
were recorded in 72% of patients.2 Sarac et al3 demon-
strated that at 5 years, 56.3% of patients who underwent
embolization for type II endoleak continued to experience
Fig 3. Freedom from continuing aneurysm growth >5 mm in patients with type II endoleak undergoing reinter-
vention and remaining untreated according to Kaplan-Meier analysis. Curves are displayed up to a value of a standard
error of <10%.
Fig 4. Summary of interventions for type II endoleaks.
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more than one embolization procedure, regardless of mate-
rial and techniques used for treatment. Gallagher et al15
found that 56% of patients with type II endoleak required
multiple reinterventions in the attempt to prevent aneu-
rysm enlargement; however, embolization (speciﬁcallylumbar more than IMA embolization) carried a low
midterm success rate.
It may be hypothesized that most reinterventions for
type II endoleak are unsuccessful because they are wrongly
applied. The source of reﬁlling might not be properly
identiﬁed, and incongruous treatment is often performed.
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serious type (I or III) endoleaks not properly identiﬁed
on imaging. The correlation frequently shown between
persisting type II endoleak and subsequent type I or III
endoleak development may not be the consequence of
lack of sealing due to aneurysm enlargement prompted
by type II endoleak but might be due to type I reﬁlling
that was originally missed but became evident on late
imaging. One of the four ruptures in aneurysms with
type II endoleak in our series was associated with evidence
of type I endoleak at the time of rupture. Whether this type
II endoleak was an originally missed type I or III endoleak
remains questionable but unclear to us on performed
imaging. Today, CTA with three-dimensional reconstruc-
tion is the best technique to use to monitor EVAR patients.
However, imaging needs to be improved to better deﬁne
type II endoleaks.
Although most of our type II reinterventions had
unsuccessful morphology outcomes (persistence of endo-
leak or sac growth), type II endoleak was not associated
with increased aneurysm mortality or rupture risk, as also
supported by most other studies.1,3,11,15 Whether this
was a consequence of an effective aggressive reintervention
strategy or there was a tendency toward overtreatment for
most benign type II endoleaks continues to be debated.
An unexpected ﬁnding of this study was the better all-
cause long-term survival in patients with type II endoleak,
although they were w1 year older than the others. We do
not have a clear explanation for this apparent counterintu-
itive difference that might be due to chance or related to
the presence of other unrecognized comorbidities or
diseases (eg, cancer) with a higher prothrombotic burden
that could have inﬂuenced the sealing of the aortic sac
and the higher mortality in patients without type II
endoleak.
Literature is conﬂicting in reporting the clinical rele-
vance and thereby the decision for the treatment of type
II endoleak,2,3,9,15,17-22 with most recent studies2,3,9,15
questioning the benignity previously suggested.17 Gelfand
et al17 in 2006 published a meta-analysis of 10 EVAR trials
involving 2617 patients and found no association between
aneurysm rupture and type II endoleak. They suggested
that type II endoleaks be followed up expecting that
most (at least one-half) will disappear spontaneously.
Deﬁnitive elective treatment was recommended only if
type II endoleak persisted for >12 months or pulsatile
sac or sac enlargement of >5 mm was detected during
a 6-month period.17 More recently, however, Sarac et al3
analyzed the long-term outcome of type II endoleak and
advocated early treatment for any type II endoleak associ-
ated with an increase in sac size.
The lack of consensus on how to currently approach
this type of endoleak was shown by a more recent meta-
analysis of EVAR studies performed by Karthikesalingam
et al.1 Articles were classiﬁed by the threshold for interven-
tion on isolated type II endoleak as conservative, selective
(intervention for >5 mm sac expansion or persistent for
>6 months), or aggressive (any type II endoleak orpersistent for >3 months). Of the overall 231 endoleaks
recorded, 56 were treated at an aggressive threshold, 104
at a selective threshold, and 71 at a conservative threshold.
Meta-regression demonstrated that no evidence for any
strategy, compared with a conservative approach, reduced
sac expansion or improved sac shrinkage.1
The inconsistent current management of type II endo-
leak reﬂects large uncertainty because of the multiple impli-
cations of type II endoleaks. Type II endoleak may
represent only a marker of some other unfavorable condi-
tion after EVAR; otherwise, total sac exclusion should
have been obtained. Currently, type II endoleak cannot
be straightforwardly deﬁned as predictable, preventable,
or that its treatment alters outcomes.
CONCLUSIONS
Occurrence and consequences of type II endoleak are
challenging to manage, and treatment with reinterventions
often results in failure. The type II endoleak remains enig-
matic and likely represents a common single marker of
various unidentiﬁed complications of EVAR sharing
multiple underlying implications. The correct origin of
type II endoleak reﬁlling cannot always be identiﬁed and
therefore effectively treated. Current knowledge is lacking
the true meaning of type II endoleak, and further effort
should be encouraged to deﬁne this apparently benign
complication of EVAR.
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